Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WU NK 101

Next Previous
Drug Profile

WU NK 101

Alternative Names: W NK; WU-NK-101

Latest Information Update: 05 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WUGEN
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Colorectal cancer; Head and neck cancer
  • Preclinical Malignant melanoma

Most Recent Events

  • 07 Dec 2024 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 21 May 2024 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Refractory metastatic disease, Late-stage disease) in USA (IV) (NCT05674526)
  • 21 May 2024 Phase-I clinical trials in Head and neck cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT05674526)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top